VP,NovelAssetAdvancement

Telix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company with offices in Australia (HQ), Belgium, Japan, Switzerland, and the United States. Our mission is to deliver on the promise of precision medicine through targeted radiation. At our core, we exist to create products that seek to improve the quality of life for people living with cancer and rare diseases. You will be supporting the international roll-out of our approved prostate cancer imaging agent and helping us to advance our portfolio of late clinical-stage products that address significant unmet need in oncology and rare diseases. Job Summary The VP, Novel Asset Advancement will serve as the executive asset owner for Telix’s CD66-targeted hematologyoncology programs, with accountability for the end-to-end strategy, advancement, and value realization of TLX66 diagnostic and therapeutic candidates through clinical development and toward registration. The position is responsible for defining and evolving the integrated asset strategy, including business case ownership, development planning, indication prioritization, and investment recommendations, while ensuring alignment with enterprise portfolio priorities. Operating as a senior individual contributor and peer to functional Vice Presidents, this role will lead cross-functional alignment and drive enterprise-level decisions, ensuring the program is strategically positioned, appropriately resourced, and executed to achieve key development, regulatory, and commercial milestones. This role is critical to advancing Telix’s first hematology-oncology product and directly impacts pipeline value, portfolio strategy, and long-term company growth. Key Accountabilities Serve as the executive asset owner for Telix’s CD66-targeted hematology-oncology programs, with full accountability for end-to-end asset strategy, progression, and value realization through clinical development and toward registration. Define and continuously evolve the integrated as